Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia.

De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, Gozzi L, Iannone A, Lo Tartaro D, Mattioli M, Paolini A, Menozzi M, Milić J, Franceschi G, Fantini R, Tonelli R, Sita M, Sarti M, Trenti T, Brugioni L, Cicchetti L, Facchinetti F, Pietrangelo A, Clini E, Girardis M, Guaraldi G, Mussini C, Cossarizza A. · 2020

Read Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. by De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, Gozzi L, Iannone A, Lo Tartaro D, Mattioli M, Paolini A, Menozzi M, Milić J, Franceschi G, Fantini R, Tonelli R, Sita M, Sarti M, Trenti T, Brugioni L, Cicchetti L, Facchinetti F, Pietrangelo A, Clini E, Girardis M, Guaraldi G, Mussini C, Cossarizza A. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7338513.txt.

Introduction

De Biasi and co-authors dissect T cell changes in COVID-19 pneumonia for Nature Communications. The immune system of infected patients is badly impaired, yet the details were unclear. The team profiled T cells and their chemical signals in patients and compared them with healthy controls.

Patients showed shifts across many T cell groups, from naive cells to worn-out, exhausted ones marked by PD1 and CD57. Their most mature T cells divided less well when stimulated. Lymphocytes poured out more inflammatory signals, including TNF, interferon-gamma, and IL-17, and the balance skewed toward the TH17 type. The picture is of an immune system both overactive and aging fast. Such maps may help target immune treatments.

Catalog record

CREATORDe Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, Gozzi L, Iannone A, Lo Tartaro D, Mattioli M, Paolini A, Menozzi M, Milić J, Franceschi G, Fantini R, Tonelli R, Sita M, Sarti M, Trenti T, Brugioni L, Cicchetti L, Facchinetti F, Pietrangelo A, Clini E, Girardis M, Guaraldi G, Mussini C, Cossarizza A.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE69 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7338513

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia By Sara De Biasi, Marianna Meschiari, Lara Gibellini, Caterina Bellinazzi, Rebecca Borella, Lucia Fidanza, Licia Gozzi, Anna Iannone, Domenico Lo Tartaro, Marco Mattioli, Annamaria Paolini, Marianna Menozzi Published in: Nature Communications DOI: 10.1038/s41467-020-17292-4 ABSTRACT Abstract The immune system of patients infected by SARS-CoV-2 is severely impaired. Detailed investigation of T cells and cytokine production in patients affected by COVID-19 pneumonia are urgently required. Here we show that, compared with healthy controls, COVID-19 patients’ T cell compartment displays several alterations involving naïve, central memory, effector memory and terminally differentiated cells, as well as regulatory T cells and PD1+CD57+ exhausted T cells. Significant alterations exist also in several lineage-specifying transcription factors and chemokine receptors. Terminally differentiated T cells from patients proliferate less than those from healthy controls, whereas their mitochondria functionality is similar in CD4+ T cells from both groups. Patients display significant increases of proinflammatory or anti-inflammatory cytokines, including T helper type-1 and type-2 cytokines, chemokines and galectins; their lymphocytes produce more tumor necrosis factor (TNF), interferon-γ, interleukin (IL)-2 and IL-17, with the last observation implying that blocking IL-17 could provide a novel therapeutic strategy for COVID-19. Subject terms: Immunological memory, Viral infection, CD4-positive T cells, Lymphocyte differentiation INTRODUCTION The dramatic pandemic caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2) that causes Corona Virus Disease-2019 (COVID-19)1, is a dramatic threat to our species that is changing daily habits and social behaviors all over the world. In Italy, the first patients with severe pneumonia of unknown origin were observed in Lombardy, first confirmed case dating to February 21st, 20202. From that moment, we saw an unpredictable number of patients with severe pneumonia, whose treatment often required admission into intensive care units. Unfortunately, many patients failed in their fight against the virus, and, as of June 18th, Italy has counted more than 35,000 deaths amongst over 240,000 infections. The pathophysiology of such virus is not yet completely understood3,4. Previous studies on severe diseases caused by other coronaviruses indicated that pulmonary inflammation is associated with increased plasma levels of proinflammatory cytokines5,6. A similar phenomenon has been described in patients with COVID-19, who can experience the so-called “cytokine storm7”. However, little is known about the cells that are involved in the production of these mediators or about the specific immune response of patients with COVID-19. Currently, we, and others, are observing that COVID-19 is much more severe in elderly patients, especially in those with different comorbidities, diabetes, and obesity, while it appears much less severe in children and pregnant women8–10. Immunological aging is associated with a chronic, subclinical inflammatory state, defined “inflammaging” where T helper (TH) type 1 lymphocytes play a crucial role, whereas children and pregnant women have a tendency to develop TH2 responses, so producing less proinflammatory molecules11,12. In order to better understand how immune response and cytokine production are orchestrated, we have deeply characterized T cells, and have studied the functional differentiation of T cells towards TH1, TH2, or TH17. For this purpose, we have employed an array of flow cytometric approaches combined with sophisticated techniques for unsupervised analysis of complex T cell phenotypes, and we have investigated the proliferative capability of different CD4+ and CD8+ T cell subsets, along with mitochondria functionality in CD4+ T cells. We have finally measured plasma levels of 31 cytokines and the polyfunctionality of T cells. A retrospective study performed by our group evidenced that a drug able to block the biological activities of IL-6, such as tocilizumab, can significantly reduce invasive mechanical ventilation or death in severe COVID-19 pneumonia (defined as the concomitant presence of a respiratory rate ≥30 breaths per minute, blood oxygen saturation ≤93%, a PaO2/FiO2 ratio <300 mmHg in room air and lung infiltrates >50% of the lung, filed within 24–48 h)13. Even if our results need to be confirmed by randomized trials, it is to note that, in comparison with the control group, COVID-19 patients treated with tocilizumab had an increased prevalence of severe infection. Here we show that COVID-19 patients have reduction in absolute numbers of CD4+ and CD8+ T lymphocytes, which display markers related to activation or exhaustion/senescence, along with altered expression of master regulators and of several chemokine receptors. Meanwhile, their CD4+ T cells have an altered cell proliferation but not mitochondria functionality, measured as mitochondrial oxygen consumption and extracellular acidification rate (ECAR). In these patients, a massive cytokine storm detectable in plasma is accompanied by an increased in vitro production of tumor necrosis factor (TNF), interferon (IFN)-γ, interleukin (IL)-2, as well as by a skewing toward the TH17 or Tc17 phenotype. This not only underlines the efficacy of a drug that contrasts cytokine storm, but also suggests the clinical evaluation of novel strategies, based upon the inhibition of the IL-17 pathway. RESULTS Characteristics of the patients We have studied a total of 39 patients, the first 21 of which were consecutively admitted into the Infectious Diseases Clinics of the University Hospital in Modena over the period of March 12th–March 30th, 2020, whereas the remaining patients were studied between April 15th and May 10th. All patients had symptoms including sore throat, fever, cough, dyspnoea, and chest pain. At admission, SARS-CoV-2 was detected in a nasopharyngeal swab specimen by real-time reverse-transcriptase PCR, and in all of them pneumonia was subsequently confirmed by X-ray. Supplementary Tables 1–4 show in details the individual clinical and biohumoral characteristics of the patients. Note that, in general, they were lymphopenic (mean: 1150 cells/μL, range: 360–2334), and in some cases lymphocyte count was very low. For the immunological analyses described below, they were compared with a total of 25 age- and sex-matched healthy controls. For those controls in which we investigated T cell phenotypes, we could measure the lymphocyte absolute number, whose mean was 2320 cells/μL, range: 1580–3130 (controls vs. patients: p < 0.0001). Characterization and count of CD4+ T cell subsets We studied CD4+ and CD8+ T cells in patients and controls using 18 parameter flow cytometry. The analysis of the data was then performed by using two complementary methodologies. In the first, we used the classical approach based upon the two-dimensional recognition of a given cell type, followed by a first gate that was required to identify the population of interest (i.e., CD4+ or CD8+ lymphocytes), followed by sequential gates to identify markers of activation, differentiation, senescence, exhaustion, regulatory CD4+ T cells, and memory stem T cells (TSCM). Data obtained with this gating strategy were then analyzed by appropriate, non-parametric statistical tests, and represented in the figures as scatter plots with means and standard errors of the mean. In the second, we performed an unsupervised analysis that considers the entire, complex scenario presented by CD4+ or CD8+ T cells. This analytical technique uses the multidimensional information obtained by FlowSOM meta-clustering coupled to a dimension-reduction method such as the Uniform Manifold Approximation and Projection (UMAP). Heat maps finally report statistical analysis (see Methods for details). The same approach was used to study CD8+ T lymphocytes. Figure 1a shows the aforementioned gating strategy that we used to compare CD4+ T cells of healthy donors and COVID-19 patients. A first gate was set on the parameters “time” and “viability”, then

Read the complete text